When was Garuda founded?

Garuda was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Garuda located?

Garuda is headquartered in Natick, United States. It is registered at 22 Strathmore Road Natick, MA 01760 USA.

How many employees does Garuda have?

As of May 04, 2025, the latest employee count at Garuda is 64.

Is Garuda a funded company?

Garuda is a funded company, having raised a total of $182M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 23, 2021.

When was the latest funding round of Garuda?

Garuda's latest funding was a $***** Series B round on Oct 17, 2024, with participation from 0 investor. Its primary sector is Transplant Medicine. In United States, the Transplant Medicine sector has seen $49.9M in funding in 2026 to date.

Where does Garuda rank among its competitors?

Garuda ranks 138th amongst 470 active competitors, of which 155 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Garuda, which secured $47.7M in Oct, 2024.

Who are the top competitors of Garuda?

Garuda's top competitors include BeiGene, Biogen and argenx. Among them, Garuda secured the most recent funding round in October, 2024.

Garuda - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of stem cell-based therapies to treat multiple diseases. The company has developed stem cell transplants by using targeted antibodies and increasing stem cell numbers by targeting self-renewal pathways. The company's pipeline includes therapeutic indications in hematologic malignancies, sickle cell disease, β-thalassemia, bone marrow failure diseases, and more.

Website: garudatx.com
Email ID: *****@garudatx.com
Registered Address: 22 Strathmore Road Natick, MA 01760 USA

Key Metrics

Founded Year

2021

Location

Natick, United States

Stage

Series B

Total Funding

$182M in 3 rounds

Latest Funding Round

Series B, Oct 17, 2024, $*****

Investors

Orbimed & 10 more

Ranked

138^th among 470 active competitors

Employee Count

64 as on May 04, 2025

Similar Companies

BeiGene & 547 more

View Garuda's full profile

Garuda is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
GARUDA THERAPEUTICS, INC CIN: 86-3018867 , United States, Active	Mar 28, 2021	-	53 (As on Dec 31, 2023)	-

Garuda has raised a total funding of $182M over 3 rounds. Its first funding round was on Sep 23, 2021. Garuda has 11 institutional investors.

Here is the list of recent funding rounds of Garuda:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 17, 2024	7215517	Series B	1832201	2852591	3549428	6064717
Feb 09, 2023	7174397	Series B	6465959	9500175	6690427	Sectoral & 2 more
Sep 23, 2021	3819087	Series A	5623562	9427040	Aisling Capital & 2 more	Ridgeback Capital Management & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Garuda's funding rounds and investors

The founders of Garuda are Sean Morrison and David Scadden. Laurie Vallas is the CEO of Garuda.

Here are the details of Garuda's key team members:

Sean Morrison: Co-Founder of Garuda.
David Scadden: Co-Founder of Garuda.

View details of Garuda's Founder profiles and Board Members

Garuda's employee count trend

Garuda has 64 employees as of May 25. Here is Garuda's employee count trend over the years:

Uncover Garuda's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Garuda include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Garuda, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	CareDx 1998, Brisbane (United States), Public	Developer of medical solutions for transplant patients	$138M	Integral Capital Partners, Intel & 24 others	73/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
138th	Garuda 2021, Natick (United States), Series B	Developer of stem cell-based therapies to treat multiple diseases	$182M	Aisling Capital, Sectoral & 9 others	45/100